Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Teva Pharmaceutical Industries ( TEVA) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.3%. By the end of trading, Teva Pharmaceutical Industries fell $0.83 (-1.6%) to $49.84 on light volume. Throughout the day, 3,815,505 shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 7,175,400 shares. The stock ranged in price between $49.80-$50.57 after having opened the day at $50.52 as compared to the previous trading day's close of $50.67. Other companies within the Health Care sector that declined today were: IMRIS ( IMRS), down 14.9%, IPC The Hospitalist ( IPCM), down 12.2%, Quidel ( QDEL), down 9.9% and China Pharma ( CPHI), down 8.8%.

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Teva Pharmaceutical Industries has a market cap of $48.7 billion and is part of the drugs industry. Shares are up 26.4% year to date as of the close of trading on Wednesday. Currently there are 9 analysts that rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 10 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the positive front, Cesca Therapeutics ( KOOL), up 28.8%, Zimmer Holdings ( ZMH), up 11.5%, Synergy Pharmaceuticals ( SGYP), up 10.9% and Cytokinetics ( CYTK), up 9.0% , were all gainers within the health care sector with Aetna ( AET) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Five-Day Winning Streak in Stocks Expected to Continue

Five-Day Winning Streak in Stocks Expected to Continue

Dow Jumps Over 300 Points, Posting Its Fifth Straight Day of Gains

Dow Jumps Over 300 Points, Posting Its Fifth Straight Day of Gains

Stock Markets Around the World Are Soaring Again

Stock Markets Around the World Are Soaring Again

Jim Cramer: The SEC Should Admit It Goofed With These Crazy Instruments

Jim Cramer: The SEC Should Admit It Goofed With These Crazy Instruments